Mersana Therapeutics

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing antibody drug conjugates that offer clinical benefit for cancer patients with significant unmet need. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Mersana Therapeutics excels in 2022, poised for oncology innovation

Mersana Therapeutics demonstrated strong performance, financial stability, and clinical progress in 2022, positioning themselves as a key player in oncology drug development.
While facing challenges in regulatory considerations and competitive dynamics, the company's strategic collaborations and pipeline advancements offer promising opportunities for future growth.
Investors should monitor Mersana's upcoming milestones, including data reporting and trial progress, as indicators of their potential for continued success and innovation.

Mersana Therapeutics progresses in Q1 with strong financials and clinical trials

Mersana Therapeutics is on track for a pivotal year with strong financials, progress in clinical trials, and plans for potential BLA submission. Challenges include diagnostic testing bottlenecks and patient pre-treatment impact on response rates. Opportunities exist in data presentations, partnerships, and subgroup analysis for improved outcomes.

Mersana Therapeutics reports improved Q3 performance and strategic partnerships

Mersana Therapeutics demonstrated improved financial performance, strong partnerships, and a focus on innovative ADC candidates. While facing challenges with clinical setbacks, the company's strategic restructuring and promising pipeline indicate opportunities for growth and success in the ADC market.

Mersana Therapeutics shows financial improvement and pipeline promise in Q1

Mersana Therapeutics demonstrated improved financial performance in Q1 2024 with reduced expenses and a lower net loss compared to the previous year.
Strengths in ADC platform advancements and promising lead candidates position Mersana well for future growth and innovation.
Challenges in clarifying key strategies and managing expenses underscore areas for improvement, while opportunities in expansion and partnerships offer avenues for advancement.

Mersana Therapeutics reports strong Q2 progress amidst financial challenges

Mersana Therapeutics demonstrated strong progress in Q2 2024 with promising clinical data for XMT-1660 and XMT-2056 ADC candidates, despite reporting a net loss.
The company's focus on optimizing dosing schedules, exploring biomarkers, and addressing resistance mechanisms underscores a commitment to advancing its pipeline.
Analysts' interest in patient responses, dosing schedules, and expansion plans highlights the market's anticipation of Mersana's future growth and innovation in the ADC space.

Mersana Therapeutics progresses ADC trials, strengthens finances, and faces resistance

Mersana Therapeutics demonstrated strong performance in advancing ADC candidates and managing finances effectively in Q3 2024.
While facing challenges such as resistance to existing ADCs, the company is well-positioned to capitalize on opportunities in innovative therapies.
Strategic planning for clinical trial expansions and business development will be crucial for Mersana's continued growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

CAMBRIDGE, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will host a virtual Analyst and Investor event on Tuesday, January 5, 2021 from 10:00 a.m. to 12:00 p.m. ET. The event will showcase the following agenda:   

Mersana Therapeutics to Host Virtual Analyst and Investor Event

Cardiff Oncology

Five Prime Therapeutics

Surface Oncology Inc

Trillium Therapeutics

Biotech investors had more than just vaccines to think about this year.

These Were the 5 Best Cancer Stocks Of 2020

CAMBRIDGE, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that preclinical mechanistic data from its novel Immunosynthen STING-Agonist ADC platform is available as a live e-poster in the virtual poster hall at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place from November 9-14, 2020.

Mersana Therapeutics Reports Preclinical Data from Immunosynthen STING-Agonist ADC Platform and Pipeline

Mersana Therapeutics' (MRSN) CEO Anna Protopapas on Q3 2020 Results - Earnings Call Transcript

- Webcast to be held on Monday, November 16, 2020, at 8:00 a.m. ET - - Webcast to be held on Monday, November 16, 2020, at 8:00 a.m. ET -

Mersana Therapeutics to Host Webinar Highlighting Immunosynthen STING-Agonist ADC Platform and Pipeline

CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today reported financial results and provided a business update for the third quarter ended September 30, 2020.

Mersana Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business Update

CAMBRIDGE, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that Anna Protopapas, President and Chief Executive Officer, will present at the 29th Annual Credit Suisse Virtual Healthcare Conference on Wednesday, November 11, at 11:00 a.m. ET.   

Mersana Therapeutics to Present at 29th Annual Credit Suisse Virtual Healthcare Conference

CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will host a conference call and webcast on Monday, November 9, 2020 at 8:00 a.m. ET to report financial results for the third quarter ended September 30, 2020 and provide business updates.

Mersana Therapeutics to Host Conference Call Announcing Third Quarter 2020 Financial Results and Business Updates

CAMBRIDGE, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will present preclinical data from its novel Immunosynthen STING-agonist ADC platform at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place virtually from November 9-14, 2020.   

Mersana Therapeutics to Present Preclinical Data from Immunosynthen STING-Agonist ADC Platform at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

- Maintained 34% objective response rate and 79% disease control rate, including two complete responses 

Mersana Therapeutics Reports Updated Interim Data from the Ovarian Cancer Cohort of the XMT-1536 Phase 1 Expansion Study

Genmab - ADR

Innoviva

Novavax

Regeneron Pharmaceuticals

Bio-Techne

Vanda Pharmaceuticals

XBiotech

These are the biotech stocks with the best value, fastest growth, and most momentum for Q4 2020.

Top Biotech Stocks for Q4 2020

Mersana Therapeutics: Poised To Capitalize As Billions Pour Into ADCs

- Company to Host Conference Call and Webcast Featuring Study Investigator, Erika Hamilton, MD on September 17, 2020 at 8:00 a.m. ET -

Mersana Therapeutics to Present Updated Interim Data from the Ovarian Cancer Cohort of the XMT-1536 Phase 1 Expansion Study at the 2020 ESMO Virtual Congress

CAMBRIDGE, Mass., Aug.  31, 2020  (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the appointment of Chuck Miller as Senior Vice President of Regulatory Affairs.

Mersana Therapeutics Appoints Chuck Miller as Senior Vice President of Regulatory Affairs

Mersana Therapeutics' (MRSN) CEO Anna Protopapas on Q2 2020 Results - Earnings Call Transcript

 - Presented positive interim expansion cohort data from XMT-1536 Phase 1 study at ASCO demonstrating a 35% objective response rate, including 10% complete response rate and 80% disease control rate in ovarian cancer

Mersana Therapeutics Announces Second Quarter 2020 Financial Results and Provides Business Update

Mersana Therapeutics (NASDAQ: MRSN) releases its next round of earnings this Friday, August 07.

Earnings Preview for Mersana Therapeutics

CAMBRIDGE, Mass., July  31, 2020  (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will host a conference call and webcast on Friday, August 7, 2020 at 8:00 a.m. ET to report financial results for the second quarter ended June 30, 2020 and provide business updates. 

Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2020 Financial Results and Business Updates

Baozun

Everbridge

Okta

Zoom Video

Here we pick five Nasdaq-listed momentum stocks that are well-poised to grow on solid prospects in the remainder of 2020.

Nasdaq's Rally to Continue in 2H20: 5 Momentum Stocks to Buy

As of late, it has definitely been a great time to be an investor in Mersana Therapeutics.

Mersana's Shares March Higher, Can It Continue?

CAMBRIDGE, Mass., June  22, 2020  (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today presented preclinical data for XMT-1592, its clinical stage Dolasynthen ADC targeting NaPi2b, as well as progress on its Immunosynthen STING-agonist ADC platform at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting.

Mersana Therapeutics Presents Preclinical Data from its Innovative Dolasynthen and Immunosynthen ADC Platforms at American Association for Cancer Research 2020 Virtual Annual Meeting

Agios Pharmaceuticals

Jounce Therapeutics

Sutro Biopharma Inc

These four cancer therapeutics stocks are poised to experience long-term growth. An investment in any of these today could bring huge rewards.

Got $1,000? Buy These 4 Cancer Stocks

Mersana Therapeutics (MRSN) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Why Mersana Therapeutics (MRSN) Could Be Positioned for a Surge

B&G Foods

Co-Diagnostics

Find Strong Buy Stocks for the Coronavirus Market Rally with this Screener

CAMBRIDGE, Mass., June  02, 2020  (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (Nasdaq:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the closing of its underwritten registered public offering of 9,200,000 shares of its common stock at the public offering price of $19.00 per share, which includes the exercise in full of the underwriters’ option to purchase additional shares of common stock. The total gross proceeds to Mersana from the offering, before deducting underwriting discounts and commissions and offering expenses, are approximately $174.8 million.

News for Mersana Therapeutics Stock (MRSN)